Aclaris Upsizes ATM Program to $150M, Adds Cantor Fitzgerald as Sales Agent
ACRS has more than doubled off its 52-week low of $1.52.
Summary
Aclaris Therapeutics upsized its at-the-market equity program to $150 million and added Cantor Fitzgerald as a sales agent, replacing a prior $100 million program.
Key Events · Financing and Capital Events · ACRS
-
ATM Program Upsized to $150M
The company replaced its prior $100 million at-the-market equity program with a new $150 million program, providing greater capital-raising flexibility.
-
Cantor Fitzgerald Added as Sales Agent
Cantor Fitzgerald joins Leerink Partners as a sales agent under the second amended and restated sales agreement, expanding the distribution network for future share sales.
-
Financial Context
The upsized ATM follows Q2 2026 results showing $170.6 million in cash and an additional $40.2 million raised post-quarter, indicating the program is a proactive liquidity measure rather than a distress signal.
Analysis · ACRS · Life Sciences
Aclaris Therapeutics replaced its existing $100 million at-the-market equity program with a new $150 million program, adding Cantor Fitzgerald as a sales agent alongside Leerink Partners. The upsized facility gives the company more flexibility to raise capital as needed, but the increased overhang could weigh on the stock. The filing comes on the same day the company reported Q2 results with $170.6 million in cash and raised an additional $40.2 million post-quarter, suggesting the ATM is a proactive liquidity tool rather than a distress signal.
At the time of this filing, ACRS was trading at $6.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $850.6M. The 52-week trading range was $1.52 to $6.52. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.